Evolution of drug therapy for classical Hodgkin lymphoma

Hodgkin's lymphoma is a malignant disease of the lymphatic system. Hodgkin's lymphoma was first described by Dr. Thomas Hodgkin in 1832 and later named “Hodgkin's disease” by Samuel Wilkes. Hodgkin's lymphoma accounts for about 24 % of all lymphomas. Hodgkin's lymphoma is classified as classical and nodular lymphoid-predominant (Nodular type of lymphoidpredominant Hodgkin's lymphoma). Classical Hodgkin's lymphoma includes the following histologic variants: nodular sclerosis variant (types I and II), mixed cell variant, classic lymphocyte-rich variant, and rare lymphoid depletion variant. Epidemiological and serological studies showed the involvement of the Epstein-Barr virus into Hodgkin's lymphoma etiology, since its genome was found in the study of the biopsy material samples from patients with Hodgkin's lymphoma. A relationship with the human immunodeficiency virus (HIV) was revealed as well, and patients infected with HIV have a significantly increased risk of developing Hodgkin's lymphoma compared to healthy people. An in-depth study of the Hodgkin's lymphoma pathophysiology revealed new therapeutic targets in the treatment of this disease. All these discoveries changed the understanding of the Hodgkin's lymphoma pathogenesis, and were important for the development of new methods of treatment. The history of therapy begins on the cusp of the 19th and 20th centuries. Over the past four decades, achievements in radiation therapy and combined chemotherapy have significantly improved overall survival of patients with Hodgkin's lymphoma. Currently, more than 80 % of patients under 60 years old with first diagnosed Hodgkin's lymphoma can be cured from this disease after first-line chemotherapy.

1. Hodgkin null. On some Morbid Appearances of the Absorbent Glands and Spleen. Med Chir Trans. 1832;17:68–114. https://doi.org/10.1177/095952873201700106

2. Gemici A, Aydogdu I, Terzi H, Sencan M, Aslan A, Kaya AH, et al. Nodular lymphocyte predominant Hodgkin’s lymphoma in daily practice: A multicenter experience. Hematol Oncol. 2018 Feb;36(1):116–120. https://doi.org/10.1002/hon.2460

3. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. by A. D. Kaprin, V. V. Starinsky, G. V. Petrova. Moscow: P. A. Herzen Moscow State Medical Research Institute – Branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of Russia, 2018, 250 p. (In Russ.).

4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). 2017, 585 p.

5. Devita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970 Dec;73(6):881–895. https://doi.org/10.7326/0003-4819-73-6-881

6. Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin’s disease: an update. Ann Oncol. 1996;7 Suppl 4:105–108. https://doi.org/10.1093/annonc/7.suppl_4.s105

7. Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-Term Results of the HD2000 Trial Comparing AB-VD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. J Clin Oncol. 2016 Apr 10;34(11):1175–1181. https://doi.org/10.1200/JCO.2015.62.4817

8. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684–691. https://doi.org/10.1200/JCO.2012.43.4803

9. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203–212. https://doi.org/10.1056/NEJMoa1100340

10. Eichenauer DA, Engert A. The evolving role of targeted drugs in the treatment of Hodgkin lymphoma. Expert Rev Hematol. 2017 Sep;10(9):775–782. https://doi.org/10.1080/17474086.2017.1350167

11. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284–292. https://doi.org/10.1016/S1470-2045(15)70013-6

12. Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458–1464. https://doi.org/10.1182/blood-2016-03-703470

13. Böll B, Borchmann P, Topp MS, Hänel M, Reiners KS, Engert A, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010 Feb;148(3):480–482. https://doi.org/10.1111/j.1365-2141.2009.07963.x

14. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May;85(5):320–324. https://doi.org/10.1002/ajh.21664

15. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998 Dec;10(6):457–470. https://doi.org/10.1006/smim.1998.0156

16. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma af- ter failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283–1294. https://doi.org/10.1016/S1470-2045(16)30167-X

17. Ansell S, Bröckelmann P, Keudell G von, Lee HJ, Santoro A, Zinzani PL, et al. HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Clinical Lymphoma, Myeloma and Leukemia. 2021 Sep 1;21:S373–S374. https://doi.org/10.1016/S2152-2650(21)01854-1

18. Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, et al. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther. 2017;10:2349–2363. https://doi.org/10.2147/OTT.S133385

19. Killock D. CAR T cells are active in Hodgkin lymphoma. Nat Rev Clin Oncol. 2020 Oct;17(10):592. https://doi.org/10.1038/s41571-020-0425-8